Physician profile
Jay B Krasner
NPI 1316950751
$4,301.68
in general payments reported to CMS, 2019-2025
28 companies · $612 in 2025
The $612 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $577 · 2021: $800 · 2022: $446 · 2023: $715 · 2024: $568 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,895.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $816.58 | 2021-2025 | |
| Pfizer INC. | $701.58 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $563.02 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $364.63 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $270.27 | 2019-2025 | Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $265.05 | 2019-2020 | |
| Exact Sciences Corporation | $218.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $213.70 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.42 | 2019-2024 | Jardiance |
| Endo Pharmaceuticals INC. | $115.82 | 2019-2022 | |
| Tolmar, INC. | $94.58 | 2023-2024 | |
| Lundbeck LLC | $82.41 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $68.97 | 2019-2025 | Camzyos |
| Kowa Pharmaceuticals America, INC. | $33.48 | 2025 | Zoryve |
| Almatica Pharma LLC | $32.96 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28.57 | 2020-2025 | Arexvy, Shingrix |
| Corium, LLC | $28.10 | 2025 | Azstarys |
| Neurocrine Biosciences, INC. | $26.83 | 2023 | Ingrezza |
| Alnylam Pharmaceuticals INC. | $25.04 | 2025 | Givlaari |
| Boston Scientific Corporation | $24.06 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.00 | 2024 | Rexulti |
| Eisai INC. | $17.85 | 2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $17.22 | 2022 | |
| Shire North American Group INC | $16.89 | 2019 | |
| Becton, Dickinson and Company | $16.65 | 2024 | Bd Onclarity |
| Acerus Pharmaceuticals Corporation | $15.99 | 2022 | |
| Ironshore Pharmaceuticals INC. | $15.87 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Krasner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.